Gorlin Syndrome



Basal cell nevus syndrome (BCNS) is an autosomal dominantly inherited condition first described in 1960 by Dr. Gorlin and Dr. Goltz [1]. BCNS is known by several other names including nevoid basal cell carcinoma syndrome, basal cell carcinoma nevus syndrome, Gorlin syndrome, and Gorlin-Goltz syndrome. Although BCNS demonstrates a high degree of penetrance, the diagnosis can be challenging due to its variable expressivity even within families [2, 3] and the age-dependent appearance of certain traits associated with this disorder. Some of the more frequent and characteristic features of BCNS include multiple basal cell carcinomas (BCCs), odontogenic keratocysts, skeletal abnormalities, palmar and/or plantar pits, calcified falx cerebri, and facial dysmorphism [1]. Other clinical features found in association with BCNS include neoplasms such as medulloblastoma, ovarian fibroma, and cardiac fibromas [4–7].


Basal Cell Carcinoma Skeletal Abnormality Facial Dysmorphism Hedgehog Signaling Pathway Nevoid Basal Cell Carcinoma Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts, and bifid rib. A syndrome. N Engl J Med. 1960;262:908.PubMedCrossRefGoogle Scholar
  2. 2.
    Anderson D, Taylor W, Falls H, Davidson R. The nevoid basal cell carcinoma syndrome. Am J Hum Genet. 1967;19:12–22.PubMedGoogle Scholar
  3. 3.
    Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. 2008;3:32.PubMedCrossRefGoogle Scholar
  4. 4.
    Kimonis VE, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Gen. 1997;69:300.CrossRefGoogle Scholar
  5. 5.
    Shanley S, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet. 1994;50:282.PubMedCrossRefGoogle Scholar
  6. 6.
    Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30:460–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Ratcliffe JF, Shanley S, Chenevix-Trench G. The prevalence of cervical and thoracic congenital skeletal abnormalities in basal cell naevus syndrome; a review of cervical and chest radiographs in 80 patients with BCNS. Br J Radiol. 1995;68:596–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Farndon PA, Del Mastro RG, Evans DG, Kilpatrick MW. Location of gene for Gorlin syndrome. Lancet. 1992;339:581–2.PubMedCrossRefGoogle Scholar
  9. 9.
    Booth DR. The hedgehog signaling pathway and its role in basal cell carcinoma. Cancer Metastasis Rev. 1999;18:261.PubMedCrossRefGoogle Scholar
  10. 10.
    Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, Gillies S, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Gailani M, Bale A. Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. J Natl Cancer Inst. 1997;89:1103.PubMedCrossRefGoogle Scholar
  12. 12.
    Levanat S, Gorlin R, Fallet S, et al. A two-hit model for developmental defects in Gorlin syndrome. Nat Genet. 1996;12:85.PubMedCrossRefGoogle Scholar
  13. 13.
    Evans DG, Farndon PA, Burnell LD, Gattamaneni HR, Birch JM. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer. 1991;64:959–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Lo Muzio L, Nocini PF, Savoia A, Consolo U, Procaccini M, Zelante L, Pannone G, Bucci P, Dolci M, Bambini F, et al. Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals. Clin Genet. 1999;55:34–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Goldstein AM, Pastakia B, DiGiovanna JJ, Poliak S, Santucci S, Kase R, Bale AE, Bale SJ. Clinical findings in two African-American families with the nevoid basal cell carcinoma syndrome (NBCC). Am J Med Genet. 1994;50:272–81.PubMedCrossRefGoogle Scholar
  16. 16.
    Farndon PA. Gorlin (naevoid basal cell carcinoma) syndrome. In: Eeles R, Easton DF, Ponder BAJ, Eng C, editors. Genetic predisposition to cancer. London: Hodder Arnold; 2004. p. 193–213.CrossRefGoogle Scholar
  17. 17.
    Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore). 1987;66:98.PubMedGoogle Scholar
  18. 18.
    Hogge WA, Blank C, Roochvarg LB, Hogge JS, Wulfsberg EA, Raffel LJ. Gorlin syndrome (naevoid basal cell carcinoma syndrome): prenatal detection in a fetus with macrocephaly and ventriculomegaly. Prenat Diagn. 1994;14:725–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Jones KL, Wolf PL, Jensen P, et al. The Gorlin syndrome: a genetically determined disorder associated with cardiac tumor. Am Heart J. 1986;111:1013.PubMedCrossRefGoogle Scholar
  20. 20.
    Lacombe D, Chateil JF, Fontan D, Battin J. Medulloblastoma in the nevoid basal-cell carcinoma syndrome: case reports and review of the literature. Genet Couns. 1990;1:273.PubMedGoogle Scholar
  21. 21.
    Woolgar JA, Rippin JW, Browne RM. The odontogenic keratocyst and its occurrence in the nevoid basal cell carcinoma syndrome. Oral Surg Oral Med Oral Pathol. 1987;64:727–30.PubMedCrossRefGoogle Scholar
  22. 22.
    Myoung H, Hong SP, Hong SD, et al. Odontogenic keratocyst: review of 256 cases for recurrence and clinicopathologic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol Endon. 2001;91:328.CrossRefGoogle Scholar
  23. 23.
    Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin. 1995;13:113–25.PubMedGoogle Scholar
  24. 24.
    Gutierrez MM, Mora RG. Nevoid basal cell carcinoma syndrome. A review and case report of a patient with unilateral basal cell nevus syndrome. J Am Acad Dermatol. 1986;15:1023–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Bree AF, Shah MR, BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome. Am J Med Genet A. 2011;155:2091–7.CrossRefGoogle Scholar
  26. 26.
    Soekarman D, Fryns JP, Casaer P, Berghe H. Van Den: increased head circumference and facial cleft as presenting signs of the nevoid basal-cell carcinoma syndrome. Genet Couns. 1991;2:157–62.PubMedGoogle Scholar
  27. 27.
    Lo Muzio L, Nocini P, Bucci P, Pannone G, Consolo U, Procaccini M. Early diagnosis of nevoid basal cell carcinoma syndrome. J Am Dent Assoc. 1999;130:669–74.PubMedGoogle Scholar
  28. 28.
    Frentz G, Munch-Petersen B, Wulf HC, et al. The nevoid basal cell carcinoma syndrome: sensitivity to ultraviolet and X-ray irradiation. J Am Acad Dermatol. 1987;17:637.PubMedCrossRefGoogle Scholar
  29. 29.
    Van der Geer S, et al. Treatment of basal cell carcinomas in patients with nevoid basal cell carcinoma syndrome. J Eur Acad Dermatol Venereol. 2008;23:308.PubMedCrossRefGoogle Scholar
  30. 30.
    Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5 % cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18:677–82.PubMedGoogle Scholar
  31. 31.
    Hsi RA, Rosenthal DI, Glatstein E. Photodynamic therapy in the treatment of cancer:current state of the art. Drugs. 1999;57:725–34.PubMedCrossRefGoogle Scholar
  32. 32.
    Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol. 1998;134:248–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol. 2003;149:1242–9.PubMedCrossRefGoogle Scholar
  34. 34.
    LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502–11.PubMedCrossRefGoogle Scholar
  35. 35.
  36. 36.
    Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of Basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011; 131:1735.PubMedCrossRefGoogle Scholar
  37. 37.
    Lebwohl M, Tannis C, Carrasco D. Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatolog Treat. 2003;14 Suppl 2:3–6. Review.PubMedGoogle Scholar
  38. 38.
    Tang JY, Aszterbaum M, Athar M, et al. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/− humans and mice. Cancer Prev Res (Phila). 2010 Jan;3(1):25–34.CrossRefGoogle Scholar
  39. 39.
    Dominguez FV, Keszler A. Comparative study of keratocysts, associated and non-associated with nevoid basal cell carcinoma syndrome. J Oral Pathol. 1988;17:39–42.PubMedCrossRefGoogle Scholar
  40. 40.
    Goldberg LH, Landau JM, Moody MN, et al. Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449. Arch Dermatol. 2011;147:839.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of DermatologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations